Gefurulimab and Generalized Myasthenia Gravis

Дата публикации: 27-07-2026 00:00:00

This randomized clinical trial compares the novel dual-binding nanobody gefurulimab vs placebo for treating anti–acetylcholine receptor antibody–positive generalized myasthenia gravis.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	First Effective Nanobody in Myasthenia Gravis Therapy	0	10.5	27-07-2026
2	Teriflunomide and Time to Clinical Multiple Sclerosis in Radiologically Isolated Syndrome	0	6.92	01-10-2023
3	Omalizumab or Oral Immunotherapy for Multifood Allergy	0	6.27	27-07-2026
4	AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia	0	9.08	01-08-2026
5	Fecal Microbiota Transplantation for Treatment of Parkinson Disease	0	4.44	01-09-2024
6	Serum GFAP Dynamics, Disease Progression, and Therapy Response in MS	0	8.04	03-08-2026
7	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
8	Rapidly Progressive Weakness in MGUS-Associated Chronic Inflammatory Demyelinating Polyneuropathy: A Rare Presentation and Review	0	7.82	20-07-2026
9	Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease	0	16.67	28-05-2026
10	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.42. Источник: jamanetwork.com.